NSW Health logs 1180 ED presentations linked to unapproved peptide use

The wire

1. 01A NSW Health report counted 1180 emergency department presentations tied to unapproved peptide injections between 1 July 2025 and September 2026; 833 mentioned retatrutide, 445 cited peptides generically or other unapproved names, 98 both.
2. 02The figures put numbers on gray-market injectable peptide harm, including anaphylaxis, in a jurisdiction where such presentations were previously described as very rare.
3. 03Retatrutide is not approved for prescription or purchase outside clinical trials; the data are presentation counts from coded ED records, not verified product analyses or confirmed causation.

From the source

Almost 1200 ED presentations linked to unapproved peptide use, figures show

The scale of harm linked to unapproved peptide use has been laid bare, with new figures revealing a sharp uptick in patients presenting to EDs in NSW after injecting peptides.